Uno studio che valuta BFB759 nell'idrosadenite suppurativa da moderata a grave (COMPASS 2-HS)
Uno Studio di Fase 2, a Dosaggio Variabile, Randomizzato, in Doppio Cieco, Controllato con Placebo per Valutare l'Efficacia e la Sicurezza di BFB759 in Pazienti con Idrosadenite Suppurativa da Moderata a Grave
This is a double-blind, placebo-controlled study where subjects are participating for approximately 36 to 40 weeks. The study compares how well BFB759 works and how safe it is compared with a placebo.
Panoramica dello studio
Stato
Stato
Condizioni
Condizioni
Intervento / Trattamento
Intervento / Trattamento
Tipo di studio
Tipo di studio
Iscrizione (Stimato)
Iscrizione
Fase
Fase
- Fase 2
- Fase 3
Contatti e Sedi
Luoghi di studio
-
-
-
Burgas, Bulgaria
- Medical Center Medconsult Burgas EOOD
-
Lovech, Bulgaria
- Medical Center Medconsult Pleven-Lovech Branch
-
Pleven, Bulgaria
- Medical Center Medconsult Pleven OOD
-
Plovdiv, Bulgaria
- Medical Center Etika Ambulatory For Specialized Outpatient Medical Care OOD
-
Rousse, Bulgaria
- Medical Center Rusemed
-
-
-
-
Alberta
-
Edmonton, Alberta, Canada, AB T5J 3S9
- Laser Rejuvenation Clinics Edmonton D.T. Inc.
-
-
Ontario
-
Richmond Hill, Ontario, Canada, L4B 1L1
- York Dermatology Clinical and Research Centre
-
Toronto, Ontario, Canada, M2N 3A6
- North York Research Inc.
-
-
Quebec
-
Québec, Quebec, Canada, QC G1W 4R4
- Centre de Recherche Saint-Louis (Quebec)
-
-
-
-
-
Ostrava, Cechia
- CCR Ostrava s.r.o.
-
Pardubice, Cechia
- Pratia Pardubice a.s.
-
Prague, Cechia
- Sanatorium of Professor Arenbergera
-
-
-
-
-
Bochum, Germania
- St. Josef-Hospital Bochum
-
Frankfurt, Germania
- Universitatsklinikum Frankfurt Klinik fur Dermatologie, Venerologie und Allergologie
-
Heidelberg, Germania
- University Clinic Dermatology Heidelberg
-
Leipzig, Germania
- University Hospital, Leipzig
-
Lübeck, Germania
- University of Luebeck
-
Munich, Germania
- Klinik und Poliklinik fur Dermatologie und Allergologie
-
-
-
-
-
Bialystok, Polonia
- NZOZ Specjal. Osrodek Dermatologiczny DERMAL
-
Lublin, Polonia
- Luxderm Specjalistyczny Gabinet Dermatologiczny prof. dr hab. n. med. Dorota Krasowska
-
Wroclaw, Polonia
- Melita Medical
-
Wroclaw, Polonia
- Uniwersytecki Szpital Kliniczny im. Jana Mikulicza-Radeckiego we Wrocławiu
-
Wroclaw, Polonia
- Wojewódzki Szpital Specjalistyczny we Wrocławi,Oddział Dermatologiczny
-
-
-
-
-
Granada, Spagna
- Hospital Universitario Virgen De Las Nieves
-
Granollers, Spagna
- Hospital Asil de Granollers
-
Las Palmas de Gran Canaria, Spagna
- Hospital Universitario de Gran Canaria Doctor Negrin
-
Madrid, Spagna
- Hospital Gregorio Maranon
-
Pontevedra, Spagna
- Complejo Hospitalario Universitario de Pontevedra
-
Valencia, Spagna
- Hospital de Manises
-
-
-
-
Arizona
-
Phoenix, Arizona, Stati Uniti, 85008
- Saguaro Dermatology
-
-
California
-
Encino, California, Stati Uniti, 91436
- Encino Research Center
-
Huntington Beach, California, Stati Uniti, 92647
- Marvel Clinical Research LLC
-
Santa Monica, California, Stati Uniti, 90404
- Clinical Science Institute
-
-
Florida
-
Boca Raton, Florida, Stati Uniti, 33021
- Skin Care Research
-
Fort Lauderdale, Florida, Stati Uniti, 33308
- Center for Skin Science and Innovation
-
Margate, Florida, Stati Uniti, 33063
- Gsi Clinical Research
-
North Miami Beach, Florida, Stati Uniti, 33126
- Ziaderm Research LLC
-
Tampa, Florida, Stati Uniti, 33607
- Clinical Trials Management, LLC
-
-
Georgia
-
Atlanta, Georgia, Stati Uniti, 30329
- DelRicht Research
-
Douglasville, Georgia, Stati Uniti, 30135
- Southeast Research Specialist LLC
-
-
Indiana
-
Plainfield, Indiana, Stati Uniti, 46168
- The Indiana Clinical Trials Center, PC
-
-
Kentucky
-
Louisville, Kentucky, Stati Uniti, 40241
- DS Research of Kentucky
-
-
Louisiana
-
Mandeville, Louisiana, Stati Uniti, 70448
- Martha Stewart
-
Metairie, Louisiana, Stati Uniti, 70006
- Clinical Trials Management, LLC
-
New Orleans, Louisiana, Stati Uniti, 70115
- DelRicht Research
-
-
Michigan
-
Auburn Hills, Michigan, Stati Uniti, 48326
- Oakland Hills Dermatology
-
Northville, Michigan, Stati Uniti, 48167
- MI Skin Innovations
-
-
Missouri
-
Wildwood, Missouri, Stati Uniti, 63040
- DelRicht Research
-
-
Nevada
-
Las Vegas, Nevada, Stati Uniti, 89145
- JDR Dermatology Research LLC
-
Reno, Nevada, Stati Uniti, 89509
- Skin Cancer and Dermatology Institute
-
-
New Jersey
-
Hackensack, New Jersey, Stati Uniti, 07601
- Schweiger Dermatology, PC
-
-
New York
-
The Bronx, New York, Stati Uniti, 10455
- Equity Medical LLC
-
-
Ohio
-
Boardman, Ohio, Stati Uniti, 44512
- Optima Research - Boardman
-
Canton, Ohio, Stati Uniti, 44718
- Apex Clinical Research Center, LLC
-
Mayfield Heights, Ohio, Stati Uniti, 44124
- Apex Clinical Research Center, LLC
-
-
Pennsylvania
-
Pittsburgh, Pennsylvania, Stati Uniti, 15213
- UPMC Department of Dermatology
-
-
South Carolina
-
Charleston, South Carolina, Stati Uniti, 29425
- Medical Univ of SC Department of Dermatology
-
Mt. Pleasant, South Carolina, Stati Uniti, 29464
- DelRicht Research
-
-
Tennessee
-
Smyrna, Tennessee, Stati Uniti, 37167
- DelRicht Research
-
-
Texas
-
Dallas, Texas, Stati Uniti, 75230
- Dermatology Treatment & Research Center
-
Frisco, Texas, Stati Uniti, 75033
- VAST Clinical Research LLC
-
Prosper, Texas, Stati Uniti, 75078
- DelRicht Research
-
Southlake, Texas, Stati Uniti, 76092
- Stryde Research-Epiphany Dermatology
-
-
Washington
-
Spokane, Washington, Stati Uniti, 99202
- Dermatology Specialists of Spokane
-
-
Criteri di partecipazione
Criteri di ammissibilità
Criteri di ammissibilità
Età idonea allo studio
Accetta volontari sani
Sessi ammissibili allo studio
Descrizione
Inclusion Criteria:
- Are adults (18 to 75 years) with a diagnosis of hidradenitis suppurativa for at least one year.
- Have moderate to severe disease not well controlled by systemic antibiotic treatment.
- Are willing to follow study instructions, attend regular visits, and avoid certain other medications during the study.
Exclusion Criteria:
- Have certain infections or other immune conditions.
- Recently used medications that could interfere with the study.
- Are pregnant or breastfeeding.
Piano di studio
Come è strutturato lo studio?
Dettagli di progettazione
- Scopo principale: Trattamento
- Assegnazione: Randomizzato
- Modello interventistico: Assegnazione parallela
- Mascheramento: Quadruplicare
Numero di armi
Armi e interventi
Gruppo di partecipanti / ArmGruppo di partecipanti / Arm |
Intervento / TrattamentoIntervento / Trattamento |
|---|---|
|
Sperimentale: Active - high dose
BFB759 loading dose followed by BFB759 maintenance high dose every 2 weeks (Q2W) through Week 14 (inclusive), which is followed by placebo Q2W at Weeks 16 through 30 (inclusive). |
BFB759 is a human mAb that inhibits multiple pro-inflammatory cytokines that contribute to the pathogenesis of multiple disease processes characterized by aberrant inflammation, including hidradenitis suppurativa. |
|
Sperimentale: Active - low dose
BFB759 loading dose followed by BFB759 maintenance mid-dose Q2W through Week 14 (inclusive). |
BFB759 is a human mAb that inhibits multiple pro-inflammatory cytokines that contribute to the pathogenesis of multiple disease processes characterized by aberrant inflammation, including hidradenitis suppurativa. |
|
Comparatore placebo: Placebo
Placebo Q2W for 14 weeks. At Week 16, participants in Placebo group who are still enrolled in the study and receiving treatment will be re-randomized (1:1) into 2 groups (Cross 1 and Cross 2) to receive BFB759
|
Placebo for BFB759 |
Cosa sta misurando lo studio?
Misure di risultato primarie
Misure di risultato primarie
Misura del risultato |
Misura Descrizione |
Lasso di tempo |
|---|---|---|
|
Efficacy of BFB759 in HS
Lasso di tempo: Baseline to Week 16 and baseline to Week 32
|
To evaluate the efficacy of BFB759 in adult male and female participants with HS as measured by the change in the number of abscesses and inflammatory nodules (AN count). |
Baseline to Week 16 and baseline to Week 32
|
Misure di risultato secondarie
Misure di risultato secondarie
Misura del risultato |
Misura Descrizione |
Lasso di tempo |
|---|---|---|
|
Evaluate the clinical activity of BFB759 using HiSCR50
Lasso di tempo: Baseline to Week 16 and baseline to Week 32
|
The HiSCR50 is defined as at least a 50% reduction in inflammatory lesion count [the sum of Abscesses and Inflammatory Nodules (AN)] and no increase in abscess count and no increase in draining fistula count relative to baseline. The threshold of 50% reduction in AN count is the defined level that is clinically appropriate and meaningful to the patient regarding improvement in quality of life and pain level. |
Baseline to Week 16 and baseline to Week 32
|
|
Evaluate the safety/tolerability of BFB759
Lasso di tempo: routinely over 21 months (about 22 visits during the course of study)
|
Record how well participants tolerate the treatment over time by recording the incidence and severity of treatment-emergent adverse events (as described by CTCAE Version 5.0) |
routinely over 21 months (about 22 visits during the course of study)
|
|
To evaluate the clinical activity of BFB759 using the International Hidradenitis Suppurativa Severity Score System (IHS4)
Lasso di tempo: Baseline to Week 16 and baseline to Week 32
|
The IHS4 is a validated tool to dynamically assess HS severity that can be used both in real-life and the clinical trials setting (Zouboulis, 2017). It is calculated by counting nodules, abscesses and dTs/sinus tracts, and calculating a total score. IHS4 = (number of nodules multiplied by 1) + (number of abscesses multiplied by 2) + [number of dTs multiplied by 4]. |
Baseline to Week 16 and baseline to Week 32
|
|
To evaluate the clinical activity of BFB759 using the Skin Pain Numerical Rating Scale (NRS)
Lasso di tempo: Baseline to Week 16 and baseline to Week 32
|
The Skin Pain NRS is a single self-reported item designed to measure skin pain severity over the previous 24 hours. The following question is asked, and the response is marked on an 11 point scale where 0 equals no pain and 10 equals the worst pain imaginable. |
Baseline to Week 16 and baseline to Week 32
|
|
To evaluate the clinical activity of BFB759 using the Hidradenitis Suppurativa-Investigator Global Assessment (HS-IGA)
Lasso di tempo: Baseline to Week 16 and baseline to Week 32
|
The HS IGA is a HS-specific global assessment. It is a 6 point ordinal scale based on objective lesion counts (Garg, 2022). Scores are calculated by the sum of abscesses, nodules (inflammatory or noninflammatory) and tunnels (draining or nondraining) in either the upper body regions or the lower body regions, whichever is greater. Scores are assigned as follows: 0 (0 1 lesions), 1 (2 5 lesions), 2 (6 10 lesions), 3 (11 15 lesions), 4 (16 20 lesions), and 5 (>20 lesions). |
Baseline to Week 16 and baseline to Week 32
|
Collaboratori e investigatori
Sponsor
Sponsor
Studiare le date dei record
Studia le date principali
Inizio studio (Effettivo)
Inizio studio
Completamento primario (Stimato)
Completamento primario
Completamento dello studio (Stimato)
Completamento dello studio
Date di iscrizione allo studio
Primo inviato
Primo inviato
Primo inviato che soddisfa i criteri di controllo qualità
Primo inviato che soddisfa i criteri di controllo qualità
Primo Inserito (Effettivo)
Primo Inserito
Aggiornamenti dei record di studio
Ultimo aggiornamento pubblicato (Effettivo)
Ultimo aggiornamento pubblicato
Ultimo aggiornamento inviato che soddisfa i criteri QC
Ultimo aggiornamento inviato che soddisfa i criteri QC
Ultimo verificato
Ultimo verificato
Maggiori informazioni
Termini relativi a questo studio
Parole chiave
Termini MeSH pertinenti aggiuntivi
Altri numeri di identificazione dello studio
Altri numeri di identificazione dello studio
- CL-BFB759-003
- COMPASS 2-HS (Altro identificatore: Sponsor)
Piano per i dati dei singoli partecipanti (IPD)
Hai intenzione di condividere i dati dei singoli partecipanti (IPD)?
Informazioni su farmaci e dispositivi, documenti di studio
Studia un prodotto farmaceutico regolamentato dalla FDA degli Stati Uniti
Studia un dispositivo regolamentato dalla FDA degli Stati Uniti
Queste informazioni sono state recuperate direttamente dal sito web clinicaltrials.gov senza alcuna modifica. In caso di richieste di modifica, rimozione o aggiornamento dei dettagli dello studio, contattare register@clinicaltrials.gov. Non appena verrà implementata una modifica su clinicaltrials.gov, questa verrà aggiornata automaticamente anche sul nostro sito web .